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ABSTRACT 
 
Fibromyalgia (FM) is a chronic non-inflammatory musculoskeletal disorder 
characterized by a variety of symptoms related to pain. A wide range of other unspecific 
symptoms may characterize the disease including fatigue, sleep disturbances, mood 
disorders, morning stiffness, anxiety, depression, cognitive dysfunction (e.g., memory 
problems, concentration difficulties, diminished mental clarity), irritable bowel and 
bladder syndrome, sexual dysfunction and sicca symptoms. In the last decade, many 
attempts have been carried out for the research of specific biomarkers in FM, but, at 
present, there are no specific markers, the diagnosis is basically clinical. The complexity 
of the disease means that there isn‘t a therapeutic treatment standards and this is 
demonstrated by the fact that pharmacological treatments are often applied in 
combination with non-pharmacological treatments. Among non-pharmacological 
interventions the most used there is the spa therapy, which includes hydrotherapy, 
balneotherapy, physiotherapy, mud-pack therapy and exercise.  
In the present work, to study the effects of both balneotherapy and mud-bath therapy 
treatments in patients affected by FM, we used rheumatological, psychiatric, 
biochemical and proteomic approach.  
Forty-one FM patients (39 F, 2 M), who fulfilled the American College of 
Rheumatology criteria received 2-week thermal therapy program comprising therapy 
once daily for 6 days/week. Twenty-one patients received mud-bath treatment, while the 
other twenty balneotherapy. Pain, symptoms, and quality of life were assessed. 
Oxytocin, brain-derived neurotrophic factor (BDNF), ATP and serotonin transporter 
levels during therapy were assayed by commercial kits. Comparative whole saliva 
proteomic analysis was performed using a combination of 2-D and nano-LC-ESI-
MS/MS spectrometry techniques. The Elisa kit was performed to validate different 
expression of transaldolase, phosphoglicerate mutase1 and zinc alpha-2-glycoprotein1 
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proteins. We observed reduction in pain, FIQ values and improvement of SF36 in both 
groups of patients treated with mud-bath or balneotherapy. The improvement of the 
outcome measures occurred with different timing and duration in the two spa 
treatments. A significant decrease of neuropeptide concentrations was observed either 
after balneo-theraphy or mud-bath therapy when assayed after twelve weeks, while no 
significant change of oxytocin levels was detected. Significant differences were 
observed for PGAM1 and zinc-alpha 2 glycoprotein protein expression. 
Our results showed that the thermal treatment might have a beneficial effect on the 
specific symptoms of the disease. In particular, while balneotherapy gives results that in 
most patients occur after the end of the treatment but which are no longer noticeable 
after 3 months, the mud-bath treatment gives more lasting results. 
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INTRODUCTION 
 
Fibromyalgia 
 
Fibromyalgia (FM) is a chronic non-inflammatory musculoskeletal disorder which can 
occur as a primary disease or in association with other autoimmune diseases (i.e. 
Rheumatoid arthritis, Systemic sclerosis, Sjogren‘s syndrome, autoimmune thyroiditis, 
tetany and chronic fatigue syndrome). In 1990, The American College of Rheumatology 
laid out several sets of criteria for the diagnosis of FM [1]. The first criterion required 
patients to report at least 3 months of widespread pain. Pain was considered widespread 
if it was present in four quadrants of the body, the right and left side as well as above 
and below the waist. Axial skeleton pain is also very commonly present in FM and is 
often considered a fifth ―quadrant.‖ The second diagnostic criterion was widespread 
pain in response to a tender point examination. In this assessment the clinician presses 
on 18 specific areas (Fig.1), the patient‘s report of pain in at least 11 of these tender 
points completes the requirements for the diagnosis of FM.  
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A wide range of other unspecific symptoms may characterize the disease including 
fatigue, sleep disturbances, mood disorders, morning stiffness, anxiety, depression, 
cognitive dysfunction (e.g., memory problems, concentration difficulties, diminished 
mental clarity), sicca symptoms, sexual dysfunction and autonomic complaints, such as 
irritable bowel and bladder syndromes [2], [3], [5]. FM syndrome exists in all ethnic 
groups and is not limited to affluent or industrialized nations. Current estimates suggest 
that between 2 and 4% of the general population suffer from the syndrome and the 
condition is more common amongst women than men, while representing 30% of 
rheumatic diseases [6],[7]. The most recent estimates from the United States suggest 
that FM affects about 5% of all women, and is the third most common rheumatic 
disorder after low back pain and osteoarthritis [8]. In a more recent study from Europe, 
the estimated overall prevalence of FM was 4.7% for chronic widespread pain, and was 
2.9% when stronger pain and fatigue criteria were simultaneously used. Symptoms 
usually appear between the ages of 20 and 55 although juvenile FM in patients as young 
as 10 years old or even less has been reported and is probably under-recognised [9]. The 
disorder may be dormant for years until triggered by infection, injury, physical or 
emotional stress or sleep disturbance [10]. The development of FM often leads to a 
premature retirement, to limitation of physical activity and waste of years with an 
acceptable quality of life, as well as the  highest rate of medical consultations. For such 
reasons, FM represents a major socio-economic problem [11], and therefore, efforts 
should be directed towards the identification of  specific diagnostic tests and specific 
treatment to reduce pain and disability. 
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Etiopathogenesis 
 
In the last decade, significant improvements have been made in the knowledge of the 
mechanisms involved in the altered pain threshold of FM patients [12], [13]. FM clearly 
differs in pathogenesis from most other rheumatological disorders in which 
autoimmunity plays a central role. Nevertheless, many attempts have been made to 
identify immunological markers in FM, leading on the whole to inconclusive results. 
Several studies have demonstrated increased levels of antiserotonin antibodies in FM, 
but these antibodies do not appear to have diagnostic relevance. Other nonspecific 
autoantibodies that have been studied in FM include antiganglioside antithromboplastin 
antipolymer antibody, anti-68/84, and anti-45kDa. These antibodies may represent 
nonspecific immune activation, and hitherto none has been useful either clinically or as 
a research end point. Since FM is characterized by widespread pain, and the origin of 
pain is inflammation, many studies have focused on the inflammatory hypothesis for 
FM, although FM is generally regarded as a non-inflammatory disease. Special attention 
has been paid on circulating pro-inflammatory cytokines as possible markers in FM 
patients [17]. The interleukin (IL)-8  has been consistently demonstrated to be increased 
in FM patients in several studies and was correlated with severity of pain [14], the same 
is true for IL-6, which is associated with hypersensitivity to pain, fatigue and 
depression. The environmental factors may play a prominent role in triggering the 
development of FM and related conditions. Environmental ‗stressors‘ temporally 
associated with the development of FM or chronic fatigue syndrome (CFS) include 
physical (and particularly skeletal) trauma, certain infections (e.g. hepatitis C, Epstein–
Barr virus, parvovirus, Lyme disease), emotional stress and other regional pain 
conditions or autoimmune disorders [15]. The environmental factors may be relevant, 
but often are not enough to trigger the disease. In fact, extensive studies have shown 
that genetic factors may predispose individuals to FM. Recent familial studies have 
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suggested an underlying genetic susceptibility on which environmental factors trigger 
the expression of symptoms. Thus, first-degree relatives of individuals with FM display 
an eightfold greater risk of developing FM compared with the general population [14]. 
The principal gene polymorphisms supposed to be a risk factor for FM are those 
implicated in mood disorders but results are often controversial. Polymorphisms in the 
serotonergic 5-hydroxy tryptamine 2A receptor (T/T phenotype), the dopamine 4 
receptor and the catecholamine o-methyl transferase enzyme (COMT), the serotonin 
transporter (5-HTT) have therefore been detected at higher frequencies in patients with 
FM [12]. In particular, the 5-HTT, which cleaves the synapse from the neurotransmitter, 
plays a crucial role in the termination and fine-tuning of serotonergic transmission. 
Alterations in 5-HTT function or expression may be involved in the pathogenesis of 
different disorders, especially those in which there are depressive symptoms. 
Offenbaecher and colleagues were the first to analyze the genotypes of the 5-HTT 
promoter locus (5HTTLPR) in patients with FM. They found that the S/S genotype of 5-
HTT occurred more frequently in FM patients than in healthy controls. This association 
seems to be interesting considering that 5-HTT is involved in many conditions that are 
either risk factors for —or frequent concomitants to— FM, such as anxiety, Bipolar 
Disorder, Psychosis, attention deficit hyperactivity disorder, and Major Depressive 
Disorder [17].  
FM is considered to be a prototypical example of a central sensitization syndrome. The 
term ―central sensitization‖, introduced by Woolf in 1983, implies a condition in which 
the central nervous system over-reacts to a variety of stimuli reaching it, thus causing 
what would normally be perceived as innocuous to end up being interpreted as painful 
and unpleasant. This basic neuro-physiological condition has been demonstrated, among 
other modalities, by the increased response of the central nervous system (CNS) to 
experimental stimulation, documented through sophisticated neuro-imaging techniques, 
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as well as by the decreased capacity of the brain to inhibit and modulate incoming pain 
signals [18]. 
FM is often associated with increased prevalence of depressive symptoms, major 
depression and anxiety. The cause and pathophysiology of FMs is unclear; 
pathophysiological hypotheses include impairment in the functioning of the 
hypothalamic-pituitary axis and alterations in specific neurotransmitters such as 
substance P, N-methyl-D-aspartate (NMDA), noradrenaline (norepinephrine) and 
serotonin (5-HT) [19]. Stressful experiences lead to depression in some people who are 
already genetically predisposed, and increase the probability of FM exordium. 
Various areas in the CNS are responsible for inhibiting ascending pain transmission 
within the spinal cord through the activity of inhibitory neurotransmitters, which 
include 5-HT, norepinephrine, enkephalins, γ-amino butyric acid and adenosine. A 
decrease in this pain inhibitory loop is an important component of central sensitization 
syndrome [16].  
 
The Other Aspects of FM 
 Oxytocin and FM 
 
The neuropeptide oxytocin is a nonapeptide produced in the paraventricular (PVN) and 
supraoptic (SO) nuclei of the hypothalamus. It is well known that oxytocin is widely  in 
many areas of the central nervous system and the spinal cord. Its effects include both 
hormonal and neuronal processes. Among the latest, oxytocin may modify behavior of 
learning and memory. Under physiological conditions oxytocin from the magnocellular 
neurons is mainly transported from the PVN to the posterior lobe of the pituitary and 
there released into the vein system and the circulation. In contrast, oxytocin acting as a 
neuropeptide/neuromodulator is released from parvocellular neurons projecting 
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elsewhere to various other brain regions. These neurons also project to the spinal cord, 
where they terminate on the presynaptic neurons of the sympathetic system in the area 
where pain modulation takes place. This latter function of oxytocin is not likely to 
contribute to changes in peripheral plasma oxytocin concentrations. Oxytocin may also 
act as a powerful stimulant for the secretion of adreno-corticotropin hormone (ACTH) 
at the anterior lobe of the pituitary. This is of interest, as perturbations in the 
hypothalamic-pituitary-adrenal (HPA) axis have been seen in FM patients. It has 
therefore been hypothesized that long-standing stress might be one important factor 
behind the pathophysiological mechanisms in the development to the FM. Oxytocin is 
known to have anti-nociceptive effects: it has been shown that a continuous infusion of 
oxytocin could increase thresholds of visceral sensory perception in Irritable Bowel 
Syndrome (IBS) patients through a modulation of the activity of afferent nerve 
pathways. Moreover, in a patient with opiate resistant cancer pain, the injection of 
oxytocin into the third ventricle was reported to result in effective analgesia [21]. The 
other studies also has revealed anxiolytic and sedative effects as well as anti-depressive 
and anti-stress effects of oxytocin. Differences of serum oxytocin expression in FM 
patients has been reported by Anderberg and colleagues [22] which suggested that 
depressed FM patients have a reduced level of neuropeptide with respect to non-
depressed FM patients. This is of interest, if we consider that often the onset of FM 
coincides with the advent of some kind of physical stress and/or emotional. Moreover, 
the steroid hormones, and estrogen in particular, stimulate the synthesis of oxytocin and 
the affinity to its receptors. The effect pattern of oxytocin as well as the dependence of 
oxytocin on estrogen make oxytocin of special interest in FM research considering that 
90% of the patients struck by the disorder are women and many of the patients  have 
their onset of the disorder in their fifth to sixth decade when estrogen levels decline 
[22]. 
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 BDNF and FM 
 
Neurotrophic factors and neurotransmitters are two major classes of intercellular signals 
that play a key role  in regulating synaptic plasticity and in cell survival throughout life. 
Brain-derived neurotrophic factor (BDNF) is a member of the nerve-growth factor 
(neurotrophin) family. By promoting neurogenesis, synaptic plasticity and cell survival, 
BDNF plays a pivotal role in the development and plasticity of the brain. Recent 
research has identified BDNF and 5-HT as two prominent signals that act in concert to 
regulate aspects of neural plasticity in multiple brain regions. In the sensory system 
BDNF is produced by a subset of primary sensory neurons (nociceptors), which are 
located in the dorsal root ganglia (DRG), that respond to tissue injury. BDNF is then 
transported in the dorsal horn where it can be released and activate trkB receptors that is 
coupled to activation of phosphatidylinositol-3-kinase and protein kinase B (Akt). 
Activation of trkB receptors by BDNF modulates two types of synapse: the first pain 
synapse in the spinal cord and the synapses in the CA1 area of the hippocampus. 
Furthermore, exogenous BDNF facilitates the release of glutamate in the hippocampus 
and GABA in the spinal cord [23]. During development of the cerebral cortex and 
hippocampus, BDNF induces the differentiation of neural stem cells into neurons and 
promotes the survival of newly generated neurons. BDNF signaling at synapses 
enhances long-term potentiation (LTP), a process of synaptic strengthening associated 
with learning and memory. BDNF also plays an important role in preventing death of 
neurons during development, and promotes cell survival during stressful conditions 
[24]. Recent findings have suggested an involvement of BDNF as a neuromediator of 
hyperalgesia and spinal central sensitization. BDNF seems to have a role in 
neurodegenerative disorders [24], in epileptic and psychogenic non-epileptic seizures 
[25], and in Major Depression Disorder,  but about this, there are conflicting results. 
Some studies have suggested an involvement of BDNF in the pathogenesis of major 
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depression which is often associated with pain syndrome, that at the level of Peripheral 
Nerve System (PNS) is mediated by BDNF [26]. Moreover, in animal and human 
studies, antidepressant treatments could increase central as well as peripheral BDNF 
levels. Recent studies have shown the significant increase of BDNF concentrations in 
serum [26] and in cerebrospinal fluid (CSF) [27] of FM patients when compared to 
healthy subjects and to chronic migraine, respectively. In a recent study [26], 
comparisons of FM patients with and without recurrent major depression as well as with 
or without antidepressive medication in low analgesic doses revealed no statistical 
significant differences, indicating that the found increase of BDNF serum 
concentrations in FM patients is independent of pre-existing major depression or 
antidepressive low dose medication [26]. However, BDNF levels were significantly 
correlated with the duration of chronic pain. This data are confirmed by Haas et al. [28] 
suggesting that BDNF is involved in the pathophysiology of abnormal pain syndromes.  
There are different and controversial reports which discuss about the role of BDNF in 
the pathophysiological mechanisms responsible for the symptoms in the FM, 
particularly anxiety and depression. In fact, Nugraha et al. [29], [30] have demonstrated 
that BDNF serum concentration among FM patients were significantly different in 
depression subgroup instead that were not observed in the subgroup anxiety.  
 
 SERT and FM 
 
Serotonin (5-hydroxytryptamine, 5-HT) is a modulating neurotransmitter produced by 
neurons located in the brainstem raphe nucleus; the axons of these 5-HT neurons 
innervate multiple cortical and subcortical brain regions to regulate an array of 
behaviors and physiologic variables, including sensorimotor control, cognition, mood, 
anxiety, sleep, food intake, and aggressive and impulsive behavior. As already said, 5-
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HT and BDNF co-regulate one another and play an important role in neuronal survival 
and synaptic plasticity in the CNS and PNS [24], [26]. 5-HT, in particular, is theorized 
to have a function in stage 4 sleep and in the pain threshold. In this regard, Russell and 
colleagues found low levels of 5-HT and tryptophan (5-HT precursor)  in serum [31] 
and in CSF [32] of group of FM patients respect to healthy controls, explaining, so, the 
use in the treatment of FM and related symptoms of all those drugs inhibiting reuptake 
of neurotransmitters. 5-HT exerts its actions by means of interaction with distinct 
receptors, which are differentiated on the basis of structures, molecular mechanisms and 
pharmacological profiles. In the past few decades, much attention has been focused on 
the specific protein which promotes the 5-HT reuptake into the pre-synaptic terminals, 
once released in the synaptic cleft, the so-called 5-HT transporter (SERT) which control 
the endogenous activity of 5-HT. For this activity, the SERT is the main target of 
antidepressants (SSRIs) such as paroxetine and fluoxetine. Moreover, it has been 
postulated that serotonergic neurotransmission has a significant function in nociception; 
alterations in 5-HT metabolism and transmission might therefore be important in the 
pathogenesis of FM. These findings support the proposal that aberrant pain perception 
in FM also results from an instability of the 5-HT system in FM. The SERT is widely 
expressed in intestinal epithelial cells, in central or peripheral serotonergic neurons and 
in platelets [19].  Since blood platelets and neurons share a similar reuptake system of 
5-HT, platelet SERT has become a useful peripheral model of presynaptic serotonergic 
activity, particularly after the demonstration of its identity with the same structure 
expressed in the CNS [33]. Studies concerning the expression and function of SERT by 
estimating the number of binding sites for [
3
H]-paroxetine and the uptake of serotonin, 
have shown an involvement of the serotonergic system in psychosis [34], eating 
disorders, such as bulimia and anorexia [35], [36] and in FM [19] with a reduction in 
the density of binding sites for platelet paroxetine coupled to a reduced rate of re-uptake 
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of 5-HT. In particular, recent clinical study have demonstrated that FM patients have 
fewer SERTs expressed on the cellular membrane than healthy subjects and a deficit in 
functionality demonstrated by a decrease in transport rate [19]. A reduced density and 
rate of SERT are consistent with previous observations indicating that levels of 5-HT 
are altered in patients with FM. 
 
 ATP and FM 
 
All living things, require a continual supply of energy to keep the organism alive. Some 
of these processes occur continually, such as the metabolism of foods, the synthesis of 
large biologically important molecules (e.g. proteins and DNA), and the transport of 
molecules and ions throughout the organism. Other processes occur only at certain 
times, such as muscle contraction. 
The Adenosine 5‘-triphosphate (ATP) performs this function acting as a special carrier 
of energy given by its chain of phosphate groups. The ATP is produced by 
mitochondria, through the ATP synthase localized on their inner membrane and forming 
part of the oxidative phosphorylation system. It is one of the end products of 
photophosphorylation, cellular respiration, and fermentation and used by enzymes and 
structural proteins in many cellular processes, cellular respiration (as a coenzyme) 
biosynthetic reactions (DNA, RNA and proteins), motility and cell division 
(maintenance of cell structure and for muscle contraction) and cell signaling. In a last 
decade, in parallel with neuroendocrine studies also tissue ultrastructural analyses have 
been carried out in affected subjects: electron microscopy has revealed disorganized 
fibers and actin filaments, altered mitochondria, defects in capillary microcirculation, 
glycogen and lipid accumulation together with DNA fragmentation in muscle biopsies 
of FM patients [37]. Moreover, the use of 
31
P magnetic resonance spectroscopy has 
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allowed the analysis of biochemical substrates in the FM muscle: higher concentrations 
of phosphodiesterase products and inorganic phosphate, have been observed in patients 
in comparison to controls, together with a decrease in phosphocreatine, ATP and 
phosphocreatine/inositol phosphate ratio in the quadriceps, confirming previous results 
in trapezius biopsies of FM patients. A reduction of ATP levels in FM subjects than 
healthy subjects is confirmed on platelets [37] suggesting a bioenergetics alteration in 
FM.  
 
Diagnosis of FM  
 
The mechanisms underlying the FM are still unclear and largely unknown, and as a 
direct consequence, the diagnosis is very difficult. The difficulty is that laboratory tests 
are normal and many of the symptoms mimic those of other conditions including many 
rheumatic complaints, psychiatric conditions and other somatic disorders such as 
depression, anxiety but also intense pain, chronic fatigue and sleep disturbances. It is 
therefore important to exclude rheumatic disorders before proceeding to a diagnosis of 
FM. It has been estimated that it takes an average of 5 years from the time the patient‘s 
first reports symptoms to the time when FM is formally diagnosed [38]. The 
Fibromyalgia Impact Questionnaire (FIQ) (Table 1) gives a good idea of the full range 
of symptoms that are regularly found. Although there is no official consensus of what 
constitutes a clinically significant score on this scale most patients diagnosed with FM 
have an FIQ total score of at least 50 (out of a maximum of 100—see Table 1). Severely 
afflicted patients frequently score 70 or more [38]. In spite of the alterations found in 
the different studies and although some criteria were established to standardize patients 
for research studies, the diagnosis of FM is basically clinical [13] and the lack of easily 
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accessible laboratory measures makes difficult to collect under the term of FM, patients 
presenting with homogeneous features and prognosis [39], [40]. 
 
 
Table 1. Fibromyalgia Impact Questionnaire (FIQ). 
Question 1 Physical functioning 
During the past week were you able to: 
Do shopping? 
Do laundry with a washer and dryer? 
Prepare meals? 
Wash dishes/cooking utensils by hand? 
Vacuum a rug? 
Make beds? 
Walk several blocks? 
Visit friends or relatives? 
Do yard work or gardening? 
Drive a car? 
Climb stairs? 
Question 2 
In the past week, how many days did you feel good? 
(1–7) 
Question 3 
How many days last week did you miss work, including housework, 
because of fibromyalgia ? 
(1–7) 
Question 4 
When you worked, how much did pain or other symptoms of your 
fibromyalgia interfere with your ability to do your work, including 
housework? 
(No problem with work < > Great difficulty with work) 
Question 5 
How bad has your pain been? 
(No pain < > Very severe pain) 
Question 6 
How tired have you been? 
(No tiredness < > Very tired) 
Question 7 
How have you felt when you get up in the morning? 
(Awoke well rested < > Awoke very tired) 
Question 8 
How bad has your stiffness been? 
(No stiffness < > Very stiff) 
Question 9 
How nervous or anxious have you felt? 
(Not anxious < > Very anxious) 
Question 10 
How depressed or blue have you felt? 
The items in question 1 are scored 0, 1, 2 or 3 for always, most of the time, occasionally or never. Because some 
patients may not do some of the tasks listed, they are given the option of deleting items from scoring. In order to 
obtain a comparable score for all patients, the mean of the scores for the rated items is used. The average score is thus 
0–3. This score is multiplied by 3.33 to obtain an adjusted score (maximum 10). Question 2 is scored inversely of the 
number of days (0 ¼ 7, 1 ¼ 6, 2 ¼ 5, 3 ¼ 4, 4 ¼ 3, 5 ¼ 2, 6 ¼ 1 and 7 ¼ 0). It is multiplied by 1.43 to obtain an 
adjusted score (maximum 10). Question 3 is directly the number of days. It is multiplied by 1.43 to obtain an adjusted 
score (maximum 10). Questions 4–10 are visual analogue scales scored on a 100 mm line with the limits given in 
parentheses. The score (0–10) is the distance (in centimetre from the left hand end). These values are not adjusted. 
Scoring: The FIQ is scored so that a higher score indicates a greater impact of the syndrome. Each of the 10 items has 
a maximum possible score of 10. The maximum possible score is thus 100. 
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To date, the diagnosis of FM is performed according to the criteria established by the 
American College of Rheumatology (ACR) in 1990 and by new diagnostic criteria have 
been proposed by Wolfe and colleagues [41] in 2010. The interpretation of these criteria 
is subject to criticism: a limit on net eleven ―tender points‖ could give rise to 
contradictions as each and every muscle tendon insertion is sore subject FM and 
tenderness of the various tender points may vary spontaneously, day after day. At 
present, there are no specific markers of FM, and many of them are used only to 
understand the pathogenetic mechanisms and to identify patient subgroups. Therefore it 
is desirable to identify precise biomarkers of FM according to feasibility and 
reproducibility criteria, for diagnostic and therapeutic purposes [13].  
 
 
Pharmacological treatment 
 
The complexity of the disease means that there isn‘t a therapeutic treatment standards 
and this is demonstrated by the fact that pharmacological treatments are often applied in 
combination with non-pharmacological treatments. Current evidence suggests a 
multifaceted treatment program based on patient education, medications to improve 
symptoms, and the aggressive use of exercise and cognitive-behavioral approaches to 
retain or restore function. Therefore, the treatment of FM symptoms requires a 
multimodal approach that has to consider somatic aspects (i.e., pain onset, location, 
quality, quantity, duration), emotional aspects (i.e., mood and anxiety), cognitive 
aspects (i.e., coping styles, beliefs about pain), and environmental aspects (i.e., social 
context and patient relationships). From the pharmacological point of view, categories 
of drugs most commonly used are: analgesics, antidepressants, muscle relaxants and 
anti-epileptics. duloxetine and milnacipran, two selective serotonin and norepinephrin 
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inhibitors, pregabalin (antiepileptic drug), and alpha2-delta agonist, have been approved 
by Food and Drug Administration for the treatment of FM symptoms. On the contrary, 
The European Medicines Agency did not approve any specific treatment for the 
symptoms of FM up to now. These drugs and a variety of other compounds are used for 
the management of FM based on their clinically meaningful and durable effect on pain 
in monotherapy trials and their beneficial effect on other symptom domains, such as 
fatigue, sleep alterations, cognition, and function [58]. The results of clinical trials of 
anti-inflammatory medications have been generally disappointing, but it has been found 
that the Tramadol (with or without acetaminophen) is effective in FM subjects [59].  
Tramadol has multiple analgesic effects: it inhibits norepinephrine and serotonin 
reuptake, and its major metabolite binds weakly to opioid receptors. Opioids may be 
helpful in treating FM pain but may induce tolerance and become habit forming and are 
also associated with adverse effects such as constipation, sedation, and nausea. Their 
use should be considered only after all other medicinal and non-medicinal therapies 
have been tried [59]. Antidepressants may restore neurotransmitter levels and modulate 
receptor expression in the hypothalamus, which normalizes hyperactivity of the HPA 
axis. Antidepressants that increase 5-HT- and NE-mediated neurotransmission are 
frequently used to treat FM and other chronic pain, particularly neuropathic pain. 
Inhibiting both 5-HT and NE reuptake transporters with tricyclic antidepressants 
(TCAs) or serotonergic and noradrenergic reuptake inhibitors (SNRIs) seems to be more 
effective in treating pain (and FM in general) than inhibiting either transporter alone 
with selective serotonergic (SSRIs) or noradrenergic re-uptake inhibitors. However, the 
efficacy of TCAs is counterbalanced by their side effects. Among the many muscle 
relaxants, those who have demonstrated greater effects are cyclobenzaprine and 
tizanidine. Finally, among the antiepileptics, are used the Alpha2-delta ligands (i.e., 
gabapentin and pregabalin) that act at a number of sites that may be relevant to pain, 
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and particularly limit neuronal excitation and enhance inhibition [58]. Finally, in 
pharmacological treatment, are sometimes used antagonists of N-Methyl-D-Aspartate 
(NMDA) receptors, which may play a key role in the nervous system reorganization 
thought to be involved in maintaining chronic pain, and its blockade can relieve pain in 
patients with FM [59]. 
 
Non-pharmacological treatment 
 
In recent years, at least three sets of guidelines have been developed by different 
medical organizations in an attempt to standardize the treatment of this condition 
(American Pain Society, European League Against Rheumatism, Association of the 
Medical Society of Germany). The current recommendations suggest that the optimal 
treatment of FM requires a multidisciplinary approach with a combination of non-
pharmacological and pharmacological treatment modalities tailored according to pain 
intensity, function, associated features, such as depression, fatigue and sleep 
disturbances, decided through discussion with the patient, so the main strategy is symptom 
management [59]-[62]. Current therapeutic strategies are aimed primarily at reducing 
pain and other symptoms that the disease involves (sleep disorders, anxiety, depression, 
etc..). In recent years there has been in-depth study regarding the complementary and 
alternative medicine as a possible solution curative or at least, possible relief for all 
patients because of debilitating symptoms have seen their daily lives strongly affected. 
Among non-pharmacological interventions the most used are physical therapy, 
psychotherapy, acupuncture, massage, and balneotherapy [63]-[66]. In the context of 
complementary medicine, the spa therapy, which includes hydrotherapy, balneotherapy, 
physiotherapy, mud-pack therapy and exercise [67]-[69],  is known to be one of the 
most recognized therapeutic strategies for the treatment of rheumatic (as well as 
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dermatological)  disorder to pain alleviation [70]. The efficacy of this treatment for 
these indications  underscores the applicability of spa therapy for the treatment of FM 
[71] but despite the long history and popularity, there are not many randomized 
controlled trials that demonstrate their effect on FM patients [71], and only a few were 
paralleled by a biological evaluation. Despite there are several articles on the effects of 
thermal therapies on FM management, its role in modern medicine is still not clear. 
About the spa treatments, balneotherapy and mud-bath therapy are the most popular 
methods used, and several studies are aimed at understanding the physiological 
mechanisms that determine these treatments in patients with FM. In Table 2 are 
represented the most important randomized controlled trials performed in FM in the last 
years[69]. Despite patients who were enrolled in these studies relate the beneficial 
effects of spa treatments, although in short term, in the reduction of pain, it is difficult to 
distinguish the effects of thermal applications from the benefits that could be derived 
from a stay in a spa environment [72].  The net benefit is probably the result of a 
combination of factors, among which, mechanical, thermal, and chemical effects are 
most prominent. A distinction can be made between the non-specific (hydrotherapeutic 
in a broad sense) mechanisms of simple bathing in hot tap water, and the specific 
(hydromineral and crenotherapeutic) mechanisms, which depend on the chemical and 
physical properties of the water used [69]. In recent years, several hypotheses have been 
formulated on the beneficial effect of the baths and , in particular, they have focused 
attention on the inflammatory process and the release of all those mediators (cytokines) 
involved in the inflammatory response. Recent studies have posited a connection 
between cytokines and certain symptoms of FM (e.g., sleep disorders, hyperalgesia, 
cognitive dysfunctions, fatigue, stress and anxiety), and it also appears that these 
molecules may play a role in the communication between the immune and nervous 
systems [73]. Particularly,  IL-6 and IL-8, whose release is caused by substance P, seem 
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to have an important role in generating the symptoms of FM, since IL-8 promotes the 
pain by sympathetic while the IL-6 is associated with hypersensitivity to pain , fatigue 
and depression. It has been shown, in fact, that the condition of major depression, for 
example, is followed by the activation of the inflammatory response with a consequent 
release of pro-inflammatory cytokines mentioned above, and therefore, the FM patients 
are treated with antidepressants who own the aim to suppress the production of IL-8 and 
IL-6 as promoters of inflammation, and thus promote the release of anti-inflammatory 
cytokines such as IL-10 [74]. The profile of pro- and anti-inflammatory properties has 
attracted considerable attention in the scientific field, and not by chance are trying to 
identify possible markers of inflammatory cytokines such as FM. In addition to high 
levels of IL-8, in diseased subjects were also found high levels of TNFα that would 
seem to be another very important factor in the inflammatory process underlying the 
FM [73], [75]. The anti-inflammatory effect of balneotherapy has been assessed on the 
basis of serum levels of some biochemical factors in patients; it is shown that in 
arthrosis treatments such as mud baths can reduce the serum levels of IL-1 [76]. The 
mud-balneotherapy therapy appears to have a positive effect on pro-inflammatory 
factors particularly involved in the genesis of pain, once again reducing the serum 
levels, we speak in this regard of prostaglandins PGE2 and leukotriene LTB4 [76]. 
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Abbreviations: Bal, Balneotherapy; VAS, Visual Analogue Scale; PAS, Pressure Algometric Scores; FIQ, Fibromyalgia Impact Questionnaire; TPC, Tender Point Count; FDI, Functional  
Disability Index; SF36, Short Form-36; AIMS, Arthritis Impact Measurement Scales; BDI, Beck Depression Inventory; HAQ, Health Assessment Questionnaire; PGA, Patient global assessment; 
IGA, Investigator‘s Global Assessment. FACIT, Functional Assessment of Chronic Illness Therapy-Fatigue Scale
Table 2.  Main characteristics of studies with spa therapy. 
Authors  Sample 
size 
Intervention Outcome 
measures 
Follow-up Results 
Buskila
 [77] A: 24 
B: 24 
 
A: Bal. (20 min daily for 10 days at 37 °C) 
B: No treatment 
VAS FIQ, TPC, 
Dolorimeter, FDI 
3 months  
 
Significant between group improvement in pain and TPC in favour of A, 
still seen after 3 months 
Neumann[78] 
 
 
A: 24 
B: 24 
 
A: Bal. (20 min daily × 10 days at 37 °C) 
B: No treatment 
SF36, AIMS, VAS 
 
3 months  
 
Significant improvement in most subscales of the SF36 for both groups. 
The improvement in physical components of the QoL index lasted 3 
months, whereas improvement in measures of psychological well-being 
was of shorter duration. Subjects in group A reported greater and longer 
lasting improvement than subjects in the group B 
Evcik[79] A: 22 
B: 20 
 
A: Bal. (20 min × 5days/week for 3 weeks 
at 36 °C) 
B: No treatment 
VAS, FIQ, TPC, 
BDI 
 
6 months  
 
The group A showed statistically significant improvement in TPC, VAS, 
FIQ and BDI at the end of the therapy and this improvement persisted at 6 
months except for BDI 
Dönmez[80] A: 16 
B: 14 
 
A: Spa therapy (thermal pool baths 20 min 
× 6 days/week for 2 weeks  
at 36 ± 1 °C, pressurizzed shower at 37°C 
or classical massage for 15min each on 
altermate days) 
B: No treatment 
VAS, FIQ, TPC, 
BDI 
 
9 months  
 
Significant improvement in pain, TPC and FIQ for group A. The pain and 
TPC results persisted for up to one month and the FIQ results for up to 6 
months 
Ardiç[76] 
 
 
A: 12 
B: 12 
A: Bal. (20 min × 5 days/week for 3 weeks 
at 37 °C) 
B: No treatment 
VAS, TPC, FIQ, 
BDI  
 
3 weeks Statistically significant improvement in VAS, BDI, TPC and FIQ was only 
found in group A at the end of the treatment cycle 
Fioravanti[72] A: 40 
B: 40 
 
A: Mud-packs (15 min daily for 2 weeks at 
45 °C) and baths (10 min daily for 2 weeks 
at 37 °C–38 °C) 
B: No treatment 
FIQ, TPC, VAS, 
AIMS, HAQ 
 
16 weeks  
 
In group A, a significant improvement in all parameters was recorded after 
mud-pack therapy and after 16 weeks 
 
 
Özkurt[81] A: 25 
B: 25 
 
A: Bal. (20 min twice/day for 2 weeks 
at 36 °C ± 1 °C) 
B: No treatment 
VAS, FIQ, BDI, 
PGA, IGA, SF-36, 
TPC 
3 months  
 
Statistically significant improvement was recorded in group A for all 
outcome parameters at the end of the treatment cycle and after 3 months, 
except for BDI and IGA 
Bazzichi[82] A:20 
B:21 
A: Bal. (20min/day for 2 weeks at 38 °C) 
B: mud-pack (10min daily at 47 °C) + Bal. 
(10min daily at 38 °C) for 2 weks 
FIQ, SF-36, HAQ, 
FACIT, other 
biological 
parameters 
12 weeks Group B showed a significant improvement of the VAS pain and SF-36. 
Group A showed a slight improvement of VAS pain and FIQ. Significant 
decrease of BDNF in both group. Group B showed a decrease of PGAM1 
and aZGP1 protein. 
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Although not totally proven, alpha1-antitrypsin (AAT) gene deficiency (AATD) are 
suspected to contribute to FM pathogenesis. One study focused on the effects of AAT 
on two women AATD and affected by FM, showed a possible relationship between 
AAT deficiency and the disease itself, it was observed that a therapy aimed at 
increasing the levels of AAT could effectively control symptoms of FM [83], [84]. The 
non-pharmacological therapies have certainly not proven the effectiveness of the 
practices which, however, are still widely exploited for the benefits it can bring, but 
despite this, intensive testing is still underway to try to understand the mechanisms that 
generate the FM and which impact the different therapeutic profiles have on it. 
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Proteomics 
 
In the last few years, it has become widely recognized that the genome only represents 
the first layer of complexity. Biological function is carried by the dynamic population of 
proteins, moreover, only the characterization of the proteins themselves can reveal 
posttranslational modifications (e.g., phosphorylation, sulfation, glycosylation, 
ubiquitination, and methylation) and give insight into protein-protein interactions and 
subcellular localization, thus providing clues about function. For these reasons, there is 
increasing interest in the field of proteomics: the large-scale identification of proteins 
contained in cells, tissues or body fluids [85]. The proteome was originally defined as 
the complete protein complement expressed by a genome [85]. However, this definition 
does not take into account that the proteome is a highly dynamic entity that will change 
based on cellular state and the extracellular milieu. Therefore, the definition of a 
proteome should specify that it is the protein complement of a given cell at a specified 
time, including the set of all protein isoforms and protein modifications [86]. Proteomic 
analyses can be used to identify the protein content in complex biological samples such 
as biological fluids and tissue extracts, and to determine the quantitative or qualitative 
differences for each polypeptide contained in different samples. It is expected that the 
proteomic profiling patterns resulting from such analyses define comprehensive 
molecular signatures in health and disease. The exploitation of a proteomic approach for 
the study of different diseases has led to the hypothesis that multiple biomarkers or a 
panel of biomarkers shown by proteomic profiling may correlate more reliably with a 
specific disease than a single biomarker or protein. Expression pattern of a known 
biomarker or correlation of expression of several known biomarkers can be a valuable 
research and clinical tool for monitoring disease or treatment progression [87]. 
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Two-dimensional electrophoresis. 
 
The identification of proteins from complex biological sample has traditionally been 
performed using 2-D PAGE coupled with mass spectrometry (MS). Two-dimensional 
electrophoresis (2-DE) separates proteins by both their isoelectric point (pI) and 
molecular weight. With this technique proteins are resolved into discrete spots, each of 
which represents a single protein that can be selectively excised and identified by MS. 
The high resolution of 2-DE allows the researcher to pick only the proteins of interest 
while bypassing the more abundant or less interesting proteins [88]. 
 
 
Sample preparation. 
 
Preparation of samples for 2-D PAGE involves solubilization, denaturation and 
reduction to completely break up the interactions between the proteins [89]. Although 
desirable, there is no single method of sample preparation that can be universally 
applied due to the diverse samples which are analyzed by 2-DE gel electrophoresis [90]. 
The ideal sample solubilization procedure for 2-D PAGE would result in the disruption 
of all non-covalently bound protein complexes and aggregates into a solution of 
individual polypeptides [91]. However, whatever method of sample preparation is 
chosen, it is most important to minimize protein modifications which might result in 
arte-factual spots on the 2-DE maps [90]. Samples containing urea must not be heated 
as this may introduce considerable charge heterogeneity due to carbamylation of the 
proteins by isocyanate formed from the decomposition of urea. Generally speaking, 
samples should be subjected to as minimum handling as possible and kept cold at all 
times [92]. Protein extracts should not be too diluted to avoid loss of protein due to 
adsorption to the wall of the vessel (glass or plastic). If samples are rather diluted and 
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contain relatively high concentrations of salts which can interfere with IEF, samples 
may be desalted [90]. Alternatively, proteins can be precipitated with ice-cold TCA / 
acetone to remove salts. Diluted samples with a low salt concentration may also be 
applied directly without further treatment, if the dried IPG strips are reswollen in 
sample solution. In this case, solid urea, CHAPS and dithiothreitol (DTT) are added to 
the sample until the desired concentration is obtained [90],[93]. 
 
 
First dimension. 
 
Iso-electro focusing (IEF) represents the first dimension of 2-DE and it is performed in 
individual immobilized pH gradients (IPG) strips. Each sample protein applied to an 
IPG strip will migrate to its isoelectric point (pI), the point at which its net charge is 
zero. There are strips with broad or narrow pH gradient (e. g., 3-10; 4-7; 4-9; 6-10; 5-6; 
9-12; 10-12). Dried gel strips containing immobilized pH gradient were commercially 
introduced in 1991 (Pharmacia Biotech, Immobiline® DryStrip Gel), their adoption for 
the first dimension of 2-DE has produced significant improvement over the classical O‘ 
Farrell carrier ampholyte-based 2-DE separation [94]. In the original 2-DE the required 
pH gradient is established by the migration of individual species of carrier ampholytes 
to their respective pI. Variations of the complex carrier ampholyte mixtures result in 
variations in the shape of the pH gradient [94]. The use of commercially prepared IPG 
DryStrip, introduced by Bjellqvist et al. [95]. and Gorg et al. [96] eliminates these 
variations. The pH gradient is immobilized by covalent incorporating Immobiline® 
acrylamide buffers into the acrylamide matrix during polymerization. Since Immobiline 
consists of discrete, relatively simple molecules, they can be manufactured very 
reproducibly pure, eliminating batch effect as demonstrated by interlaboratory 
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comparison [94], [97]. Further, pI resolution to 0.01 pH unit can be achieved [95]. The 
acrylamide matrix with the Immobiline, acrylamido buffers is cast onto a backing sheet, 
polymerized, washed and dried. The backing gives the strips size stability and simplify 
handling. The dried strips can be rehydrated in various buffers and additives that would 
inhibit polymerization if included at the time of casting [94]. 
 
 
Second dimension. 
 
Prior to the second dimension (Sodium Dodecyl Sulphate PolyAcrylamide Gel 
Electrophoresis-SDS-PAGE), the IPG strips are equilibrated twice with gentle shaking 
in a solution containing urea and glycerol in order to diminish electroendosmotic effects 
[96] which are held responsible for reduced protein transfer from the first to the second 
dimension. DTT, a reducing agent, is added to the first and iodoacetamide (IAA) to the 
second equilibration step [98]. IAA is added to the equilibration buffer in order to 
remove excess DTT (responsible for the "point streaking" in silver stained patterns) 
[99]. After equilibration the strips are applied to vertical SDS gels in order to perform 
electrophoresis and to separate proteins according to their molecular weight. 
Polypeptides separated can be visualized by Coomassie Blue, silver staining, 
fluorescence or autoradiography, or by "specific" stains such as glycoprotein staining or 
immunochemical detection methods [90]. Whereas the "general" protein stains are 
carried out in the electrophoresis gel directly, immunochemical detection methods are 
usually performed after electrophoretic transfer ("blotting") of the separated 
polypeptides from the electrophoresis gel onto an immobilizing membrane [100], [101]. 
Today, among the variety of methods used for protein detection after gel 
electrophoresis, fluorescent methods offer an interesting compromise, especially for 
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detection linearity and for compatibility with mass spectrometry [102]. Stained spots 
excised from the electrophoresis gel can be identified by mass spectrometry. 
 
 
Mass Spectrometry, nanoLC-ESI-MS/MS 
 
In traditional protein chemistry, proteins were identified by de novo sequencing using 
automated Edman degradation. Today, this technique is replaced by mass spectrometry, 
which is becoming one of the most powerful techniques in protein chemistry. The 
reason for this is the increase in sensitivity (until 1000fold) and the speed of analysis.  
Today, the Nanoscale liquid chromatography coupled to tandem mass spectrometry 
(nano LC–MS/MS) has become an essential tool in the ﬁeld of proteomics, due to your 
enormous analytical advantages when dealing with sample-limited situations. Tandem 
mass spectrometry has been used as a microscale de novo sequencing tool for peptides 
because collision-induced dissociation (CID) followed by product ion scanning provides 
systematic fragment information of amino acid sequences. Further improvement in 
peptide sequencing sensitivity was accomplished by the development of nano 
electrospray combined with a peptide sequence tag approach for protein identification in 
databases. Because even one peptide is sufficient to identify a unique protein, this 
approach is more powerful for protein identification in proteome-scale experiments than 
the peptide fingerprinting approach where several peptide masses from one protein are 
used for identification [103]. For proteomic analysis, proteins are normally ﬁrst cleaved 
into peptides by enzymatic digestion (i.e., usually by trypsin) and subsequently, 
separated by reversed phase (RP) Nano LC before data-dependent MS/MS analysis 
[104]. The typical microcolumns for nanoLC are prepared using RP materials with a  3-
10μm diameter packed into fused silica capillaries with a 12-100μm diameter. In ESI-
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MS, a spray needle is used as a restrictor for packed particles to prepare a fritless 
column, to minimize the post-column dead volume [103]. Generally, smaller colums at 
a lower flowrate combined with real nanoelectrospray conditions give higher sensitivity. 
For peptides, in combination with C18 stationary phases, acidic conditions are usually 
used: Trifluoroacetic acid (TFA) is one of the most popular reagents because of higher 
peak capacity with smaller peak width while Acetonitrile or Methanol have been used 
as an organic solvent in off-line infusion. Finally, because of the low flowrate, and the 
small size ranges of proteomic samples (<100μl), trap columns are useful to reduce the 
injection time. Spots of interest are excised from the gel and treated with tripsin, an 
enzyme that cleaves C-terminal to arginine (R) and lysine (K). The mixture of protein 
fragments (peptides) obtained after digestion is purified and subjected to mass analysis. 
 
 
Saliva 
 
In terms of disease diagnosis and prognosis, a human body fluid (e.g., blood, urine, or 
saliva) appears to be more attractive than tissue because body fluid testing provides 
several key advantages including low invasiveness, minimum cost, and easy sample 
collection and processing [105] Serum or plasma have been the fluids most often used 
in disease diagnosis but an issue with these samples is sample preparation and handling. 
Another critical point is the complexity of the proteome [105]. Most importantly, when 
searching for biomarkers in blood, there are two serious consideration. First, the 
concentration of substance can vary over 9 orders of magnitude, which severely 
diminishes the likelihood of detecting those at the lower end of the scale; besides, blood 
is composed of peptides, proteins and cells that have half-lives ranging from seconds to 
weeks, or even a month or more. As a consequence, the presence of a given substance 
might not accurately reflect the current state of the organism [106]. By contrast, human 
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saliva is becoming a more attractive source for proteomic profiling because it can 
provide clues to local and systemic diseases and conditions. The physiology of the oral 
cavity is such that the flow of secreted fluid is continually flushing and refreshing the 
fluid content of the mouth. Therefore, the composition of the saliva temporally reflects 
the metabolic activity of the secretory elements generating that fluid at any 
moment[106]. The logistical advantages of salivary diagnostic are obvious; saliva is 
relatively easy to collect in sufficient quantities for analysis, and the costs of storage and 
shipping tend to be lower than those for serum and urine. Non-invasiveness, and ease of 
sample processing are advantageous as well [105], [107]. In addition, for health care 
professionals and scientists, saliva tests are safer than blood tests, which are more likely 
to result in exposure to HIV or hepatitis [105]. On the other hand, a variety of factors 
may influence the rate of salivary flow and its physiologic characteristics, including 
circadian rhythms and activities such as exercise, and these factors should be taken into 
account when saliva is used as a diagnostic fluid [107]. 
 
 
Proteomic Biomarkers and FM 
 
In the last few years, several attempts have been carried out to identify specific 
biological markers in FM, but so far no tests have proven to be of diagnostic validity. 
Recently, our research group focused its attention on the proteomic profiling of whole 
saliva (WS) in FM patients respect to healthy controls, in order to evaluate salivary 
biomarkers [20]. Proteomic may be defined as a large spectrum study of the expression 
and identification of proteins expressed in one tissue or organism [42], [43]. This 
approach has already been used to explore biomarkers in different disorders, such as 
systemic sclerosis [44]-[46], Sjögren's syndrome [47]-[49], or as research tool in thyroid 
neoplasms [50]-[52] or FM [17], [20], [82]. In this case we observed the exclusive and 
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significant over expression of two enzymes in FM saliva: transaldolase and 
phosphoglycerate mutase I (PGAM1). Transaldolase is an enzyme of the non-oxidative 
phase of the pentose phosphate pathway which is involved in the generation of 
nicotinamide adenine dinucleotide phosphate reduced (NADPH) [53]. Many evidences 
have shown that oxidative stress and nitric oxide may play an important role in FM 
pathophysiology [54], but it is still unclear whether oxidative stress abnormalities 
documented in FM are the primary or secondary [55], [56]. Moreover, transaldolase 
links the pentose phosphate pathway to glycolysis. From this point of view, it is 
intriguing that another enzyme involved in the glycolysis, the PGAM1, was differently 
expressed in FM patients [57], [20]. PGAM1 is an enzyme of the glycolytic pathway 
that catalyzes the conversion of 3-phosphoglycerate (3PG) to 2-phosphoglycerate 
(2PG). This enzyme also promotes glycolysis and ATP production via the Citric Acid 
Cycle and the electron transport system, through its substrate and product (3PG and 
2PG, respectively) modulates two other biosynthetic pathways derived from glycolysis: 
the oxidative branch of the pentose phosphate pathway and the serine biosynthesis 
pathway. 
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AIM 
 
The present study describes the results of a multidisciplinary approach 
(rheumatological, psychiatric, biochemical, proteomic) of a research project entitled 
"Effects of balneotherapy treatment at Montecatini Terme spa on biochemical markers 
in fibromyalgia patients" funded by the Foundation for Scientific Thermal Research 
(FORST) and conducted in collaboration between the Montecatini spa (PT, Italy) and 
the University of Pisa (Department of Pharmacy and Department of Clinical and 
Experimental Medicine, Division of Rheumatology) for the evaluation of the effects of 
balneotherapy and mud-bath therapy on 41 patients affected by FM. 
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METHODS 
 
Patients 
 
Forty-one primary FM patients (39 female, 2 male) aged  between 31 and 69 years 
participated in the study. The patients enrolling was conducted in steps: in the first step 
we consulted about 300 medical records in order to individuate those FM patients 
without circulatory problems or heart disease or other conditions which influence the 
inclusion in the study and who lived in areas adjacent to the spa. The patients were 
contacted by letter or by phone to explain  them the nature of the study and give a first 
date of appointment. The response rate of patients with this first contact was 30%. The 
percentage of patients who were found unsuitable or that after the first visit did not 
come back was 10%.  At the first visit the patients were clinically classified by a 
rheumatologist according to the 1990 ACR criteria [1], which include the following: 
pain for more than 3 months from all of the four body quadrants, axial skeletal pain and 
pain upon digital palpation of at least 11 out of 18 specific bilateral points. The 
exclusion criteria were represented by the presence of contraindication to any form of 
balneotherapy such as a peripheral vascular disease; having taken balneotherapy in the 
last 12 months; pregnancy or nursing. The demographic characteristics of 41 FM 
patients have been summarized in Table 2. During this first visit, the rheumatologist 
administered the clinical questionnaires. After fulfilling the inclusion criteria and 
obtaining the written informed consent, the patients were randomly assigned to 
balneotherapy treatment. The patients were randomized using a computer-generated 
random number list by an independent investigator, and allocated to either the mud-bath 
therapy or balneotherapy treatment. Almost all the selected patients came from areas 
near the spa and continued to live at home and carry out their daily routines, with the 
exception of two patients who preferred to stay in hotels close to the spa. Daily 
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treatment lasted 12 consecutive sessions except Sundays at MontecatiniTerme spa (PT, 
Italy, Salse-Sulphate-Alkaline waters, prevalently formed of sodium chlorides and 
sodium and magnesium sulphates [Na
+
, Cl
-
, Mg 
++
, So
4–-
],  fixed residue at 180°C: 19.2 
g/l).  Twenty patients were treated with balneotherapy for 20 minutes a day and the 
other 20 patients were treated with mud-bath therapy. The mud was applied on the body 
surface at a temperature of 47°C for 10 min daily in the morning, followed by 
immersion in thermal water at 38°C for 10 min. After the spa therapy,  a period of rest 
for both groups in a hot bathrobe followed. The entire daily treatment lasted an hour. 
Among the patients treated with balneotherapy, four did not take any medicines, four 
took antidepressants, one took anti-inflammatory drugs, four took analgesics, four took 
muscle relaxants and two took antiepileptics. Instead, among the patients treated with 
mud-bath therapy, four did not take any medicines, seven took antidepressants, four 
took anti-inflammatory drugs, one took analgesics, and two took antiepileptics. The 
patients were receiving drug treatment for at least three months, the doses were stable 
and no new drugs were added during the spa treatment.  
 
 
Clinical evaluations 
 
At baseline (T0), after 2 weeks (T1)  and after 12 weeks (T2) the  patients were 
clinically evaluated using the following outcome measures: the Fibromyalgia Impact 
Questionnaire (FIQ), the evaluation of tenderness at tender points by digital pressure, a 
10-cm visual analogue scale (VAS) for pain and tiredness (0 indicates no symptoms 
whereas 10 is the worst condition), the presence of absence of minor symptoms of FM 
(fatigue, headache, sleep disturbances, gastro-intestinal symptoms and other symptoms),  
the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT fatigue) Scale 
(version 4), the Health Assessment questionnaire (HAQ) to determine physical 
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disability and the SF-36 questionnaire (ShortForm with 36 questions), a well-
documented, self-administered quality of life (QoL) scoring system. 
The FIQ (Fibromyalgia Impact Questionnaire) [107]-[109], is a questionnaire of 10 
questions that assess the physical, occupational, depression, anxiety, sleep, pain, 
stiffness, fatigue and well-being in patients with FM. The higher scores indicate a worse 
quality of life. The  HAQ ("Health Assessment Questionnaire") [110], [111] is used for 
patients with various rheumatic diseases: disability is assessed by 8 categories of 
questions designed to verify if the patient has difficulty in dressing, arising, eating, 
walking, bathing, reaching objects, shaking objects and doing activities. 
The FACIT-Fatigue Scale questionnaire (Functional Assessment of Chronic Illness 
Therapy-Fatigue Scale) [112] is a collection of questions related to the quality of life 
aimed at chronic disease management. It consists of 13 questions that investigate the 
fatigue, the ability to perform everyday skills, the need for sleep, the need of help to 
perform daily activities, and how physical state affects the psychic state. 
The health status questionnaire SF-36 [113] is a generic, multi-dimensional 
questionnaire articulated through 36 questions assembled in 8 different scales. The 36 
questions relate conceptually to 8 health domains: PF-physical functioning (10 
questions), RP physical role (4 questions), ER emotional role (3 questions), BP bodily 
pain (2 questions), GH general health (5 questions), VT vitality (4 questions), SF social 
functioning (2 questions) and MH mental health (5 questions). The higher scores are 
related to better health. Trained psychiatrists have evaluated the patients using the 
Structured Clinical Interview Scale (SCID) for DSM-IV [114], [115]. For the entire 
period of the study, the patients were recommended not to modify their pharmacological 
treatment, while the use of other drugs were not permitted. If serious adverse events 
occurred, the patients was excluded from the study.  
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Table 3. Tests of clinical evaluation used to classify each patient 
Specific tests for evaluating FM 
 Fibromyalgia Impact Questionnaire (FIQ) 
 finger pressure of tender points 
 Visual analogue scale (VAS) for minor symptoms in FM (e.g., fatigue, sleep 
disorders, migraine, stiffness in the morning, gastro-intestinal symptoms). 
 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT fatigue) Scale 
(version 4) 
Evaluation of other parameters 
 Health Assessment questionnaire (HAQ) to determine the physical disability 
 Pittsburgh Sleep Quality Index questionnaire (PSQI) to determine quality and sleep 
disorders. 
 SF-36 questionnaire (Short Form with 36 questions), a well-documented, self-
administered quality of life (QoL) scoring system. 
Assessment of Psychiatric aspects 
 Structured Clinical Interview (SCID) for DSM-IV 
 Experiences in Close Relationships (ECR)  
 Jealousy questionnaire (QUEGE) 
 
The study protocol has been approved by the Ethics Committee of the ―Azienda 
Ospedaliera Universitaria Pisana‖. 
 
 
Whole saliva samples: collection and preparation 
 
Unstimulated whole saliva (WS) samples were collected early in the morning (between 
8 and 10 a.m) in standard conditions, i.e. all the subjects were asked to be on an empty 
stomach, without having assumed any drinks or any kind of food (including gum or 
candies) since the night before. In order to minimize the  degradation of the proteins, the 
samples were processed immediately and kept on ice during the process. Between 1-3 
ml saliva was obtained from each subject. To remove the debris and the cells, a 
centrifugation at 14000 g for 30 min at 4 °C, was performed and the protein amount of 
resulting supernatants was estimated using a DC protein assay from Bio-Rad. Bovine 
serum albumin (BSA) was used as a standard. WS samples from individual patients 
(corresponding to 200µg) were solubilized with rehydration solution (7M Urea, 2M 
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thiourea, 4% CHAPS, 60 mM DTT, 0.002% bromophenol blue)  filled up to 400µl and 
supplemented with 1.2% IPG Buffer pH3-10.  
 
 
Blood samples preparation 
 
Whole venous blood samples (30 ml) were drawn from overnight fasting subjects 
between 8:00 and 9:00 am at the division of Rheumatology, University of Pisa. The 
amounts of blood (5ml) were collected into serum tubes, and centrifuged at 200 x g for 
15 minutes at 20-25°C for BDNF serum determination. The remainders were collected 
in vacutainers containing EDTA (1 mg/ml) as anticoagulant and processed as follows:  
a) 10 ml was transferred to centrifuge tubes containing aprotinin (Sigma, Milan, 
Italy) (0.6 TIU/ml of blood) protease inhibitor then centrifuged at 1,500 x g for 
15 minutes at 4°C and the resulting plasma was collected and kept at –80 °C 
until the oxytocin assay.  
b) 10 ml was centrifuged at 200 x g for 10 minutes at 20-25°C (RT) obtaining 
platelet-rich plasma (PRP) and platelets were counted automatically with a flux 
cytometer (Cell-dyn 3500 system; Abbott, Milano, Italy). For [
3
H]paroxetine 
binding, platelets were precipitated by centrifugation at 10000 x g for 10 
minutes at 4 °C whereas for ATP assay, aliquots of PRP were centrifuged at 200 
x g for 20 minutes at room temperature: 
c) 5ml was centrifuged at 1,500 x g for 15 minutes at 4°C and  the resulting plasma 
was collected and kept at –80 °C until the BDNF plasma assay. 
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Platelet membrane preparation. 
At the time of the assay, the platelets were re-suspended in 10 volumes (w:v) ice-cold 5 
mMTris-HCl buffer (pH 7.4) containing 5 mM EDTA and protease inhibitors 
(benzamidine 160μg/ml, bacitracine 200μg/ml; trypsine soy inhibitor 20μg/ml). After 
the  homogenization by Ultraturrax, the samples were centrifuged at 48,000 g for 15 
minutes at 4°C. The pellets were washed twice in 10 volumes (w:v) ice-cold 50 
mMTris-HCl buffer (pH 7.4) and the resulting membrane pellets were suspended in the 
[
3
H]paroxetine binding assay buffer (50 mMTris-HCl buffer pH 7.4, 120 mMNaCl and 
5 mMKCl). The protein content was determined by the Bradford‘s method (Bio-rad), 
using γ-globulins as the standard. 
 
 
[
3
H]-Paroxetine binding assay 
 
The SERT binding parameters (maximal binding capacity, Bmax, fmol/mg protein; 
dissociation constant, Kd, nM) were evaluated in platelet membranes by measuring the 
specific binding of [
3
H]-paroxetine. The [3H]-paroxetine Bmax represents the specific 
density (number) or the degree of SERT protein expression on platelet membranes of 
each enrolled subject, while KD being the main index of ligand-to-protein affinity 
[116]. Saturation experiments were carried out as follows: 100 μl of membranes (50–
100 μg proteins/tube) were incubated in assay buffer (50 mM Tris-HCl, 5 mM KCl, 120 
mM NaCl, pH 7.4)  with five increasing concentrations of [
3
H]-paroxetine, (0.08 -1.5 
nM) in a final volume of 2 ml. Non-specific binding was performed, for each [3H]-
paroxetine concentration point, in the presence of 10 μM fluoxetine, as displacer. 
Incubation was performed for 60 min at 22-24°C and halted by rapid filtration using 
Wathman GF/C glass fiber filters in a Brandell filtration apparatus. The  filters were 
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washed three times with 5 ml ice-cold buffer assay and  radioactivity was counted with 
a scintillation β-counter Packard 1600 TR. Specific binding was obtained by subtracting 
residual binding in the presence of 10 μM fluoxetine from total binding. The 
experiments was performed in duplicate. 
 
 
Oxytocin Determination 
 
Aliquots of plasma (6 ml) were immediately acidified with 6 ml of HCl 0.1 N and 
centrifuged at 48,000 x g for 10 minutes at 4°C. C-18 Sep-pack columns (Waters) were 
equilibrated by washing with 10 ml of methanol followed by 20 ml of water. Acidified 
plasma solutions were loaded into the equilibrated C-18 Sep-pack columns. Then the 
columns were washed slowly with 10 ml of 4% acetic acid followed by 2 ml of 
methanol and the washing liquids were discarded. Oxytocin was then eluted with 
methanol, the eluates were evaporated in a centrifugal concentrator under vacuum 
(Speedvac) and the remaining lyophilized samples were stored at –80°C.  
Quantitative determination of Oxytocin in samples was measured by using a 
competitive Oxytocin Enzime Immunoassay kit (EIA kit, Enzo Life Sciences) according 
to the manufacturer‘s instructions. The optical density was  read at 405 nm with a 
microplate reader (Victor Wallac, Perkin Elmer).The Lower Limit of Detection of these 
assays was less than 12 pg/ml. 
 
 
Plasma and serum BDNF determination 
 
The BDNF was measured in plasma and serum samples with commercial enzyme-
linked immunosorbent assay (ELISA) kits according to the manufacturer‘s instructions 
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(Promega, Emax ® ImmunoAssay System, Wallisellen, Switzerland). To measure the 
amount of total BDNF, plasma acidification and subsequent neutralization of the 
samples were followed before proceeding with the ELISA protocol, according to 
instruction. The absorbance was measured at 450 nm.  The minimum of detection was 
of 15.6pg/ml of BDNF. 
 
 
Intracellular adenosine 5’-triphosphate (ATP) determination 
 
The ATP was released from platelet suspension using an Adenosine 5′-Triphosphate 
Bioluminescent Somatic Cell Assay Kit which follows the luciferin–luciferase reaction 
(Sigma-Aldrich St. Louis, MO). In the Eppendorf tubes, aliquots of platelet suspension 
(100 cells/50 μL) were incubated with 100 μL somatic cell ATP releasing reagent, 50 
μL of sterile distilled water or 50 μL (200 ng) ATP standard solution (ATPstd). For 
luminescence analysis, a volume (100 μL) of these solutions was transferred into a 96 
multi-well plate (OptiPlate™, Perkin-Elmer). After the addition of 100 μL of ATP assay 
mix, containing luciferin and luciferase, the luminescence light emission was directly 
measured by a Wallac 1420 Multilabel Counter (Perkin-Elmer, Inc.,CA) using a 
software-programmed for luminometry. 
The sample platelet ATP amount (ATPs) was calculated by the equation: 
 
ATPs = (ATPstd) x (Ls)/L (s+std) – L(s) 
 
where ATPstd was the ATP known concentration (in moles), added as internal standard, 
(I.S).; L(s) was the light emitted by ―blank‖ sample without I.S., and L(s+std) was the light 
emitted by sample containing I.S. 
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2-D analysis 
 
In a first phase, twenty randomly selected samples were pooled according to thermal 
treatment (balneotherapy or mud-bath therapy)  into three groups corresponding to the 
three times of sample collection and 2-D analysis was performed in triplicate. 
Isoelectrofocusing (IEF) was carried out by using 18 cm Immobiline Dry-Strips (GE 
Healthcare) with a linear, pH 3–10, gradient. 200 µg of proteins were filled to 400 µl 
with rehydration buffer supplemented with 1,2% (v/v) IPG Buffer, pH 3–10 (GE 
Healthcare). IEF was performed at 16 °C on an EttanIPGphor II apparatus (GE Health 
Care) according to the following schedule: the samples were applied by in-gel 
rehydration for 24 h using the Reswelling Tray for the passive rehydration, then the 
Immobiline Dry-Strips were transferred onto Manifold and were applied a constant 
voltage at 200V for 2:30h and then at 300V for 1h.  At this point the voltage was 
linearly increased from 300 to 5000 for 3h, and then the proteins were focused for up to 
75 000Vh at a maximum voltage of 8000 V for 8:30h. To prepare the IPG strips for the 
second dimension, the strips were first equilibrated 15 min at room temperature in a 
buffer containing 50 mM Tris-HCl, pH 8.8, 6 M Urea, 30% glycerol, 2% SDS, 0.002% 
bromophenol blue, 1% DTT, followed by a second equilibration for 10 min in the same 
buffer except that DTT was replaced by 2.5% IAA. Subsequently, the IPG strips were 
applied horizontally on top of 12.5% SDS-polyacrylamide gels (21x18x0.15cm) and 
electrophoresis was performed using the PROTEAN Plus Dodeca Cell system (Bio-
Rad) with constant amperage at 96mA until the dye front reached the bottom of the gel 
(about 1h) and then at 192mA over-night (about 14h) at 15°C. 
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Staining and image analysis 
 
The gels were stained with Ruthenium II tris (bathophenanthrolinedisulfonate) 
tetrasodium salt (SunaTech Inc.). Briefly, after electrophoresis, the gels were fixed in 
1% phosphoric acid (v/v) and 30% ethanol for 1h at room temperature and then were 
first stained overnight with 1 mM ruthenium complex (RuBP) in 1% phosphoric acid 
and 30% ethanol. Afterwards, the gels were destained for 4–6 hours in 1% phosphoric 
acid and 30% ethanol and rinsed in water prior to acquisition on fluorescence [102] by 
―ImageQuant LAS4010‖ (GE-Healthcare). The images were analyzed with the 
ProgenesisSameSpot (Nonlinear Dynamics) software. This software generates 2DE 
analyses which are robust and accurate. The gels were aligned to place all spots in 
exactly the same location, and then spot detection produced a complete data set since all 
gels contain the same number of spots, each matched to its corresponding spot on all 
gels. A comparison between three classes was performed. The software included 
statistical analysis calculations such as Anova p-value and False Discovery Rate (q-
values). The gels were compared and protein spots with a >2-fold spot quantity change, 
P < 0.05 and q value < 0.05 (herein referred to as ‗‗diﬀerentially expressed proteins‘‘) 
were selected, were excised from the gel and were sent to Proteomic Core in Geneva 
(Switzerland) to identify the proteins using nanoLC-ESI-MS/MS.  
  
 
Enzyme linked-Immunosorbent Assay of Transaldolase, Phosphoglicerate 
Mutase1 and Alpha-2-Glycoprotein1 Zinc Binding proteins 
 
The concentration of Transaldolase (TALDO1), Phosphoglicerate Mutase1 (PGAM1) 
and Alpha-2-Glycoprotein1, Zinc Binding (aZGP1) was determined in all WS samples 
of individual patients (40 patients) at each time of collection (T0, T1, T2) using a 
commercial ELISA kit (USCN Life Science Inc., Wuhan, China) according to the 
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manufacturer‘s instruction. The limit of detection of each kit was 0.056ng/mL, 
1.5ng/mL and 0.57ng/mL for TALDO1, aZGP1 and PGAM1, respectively. Amounts of 
100 µl of no diluted WS samples were assayed except for PGAM1 where we operated a 
1:2 dilution in phosphate buffer saline PBS 20mM pH 7.15, of WS samples. 
Absorbance values were measured spectrophotometrically  at a wavelength of 450nm 
by Wallac Victor 2, 1420 label (Perkin Elmer). 
 
 
Statistical Analyses 
 
Clinical data were represented as median (minimum and maximum). The data were 
evaluated using non-parametric statistical methods. Friedman‘s test for repeated 
measures with post hoc test for multiple comparison was used to compare the baseline 
values and the other time points values in each treatment. Mann-Whitney U test was 
used to compare the independent groups. Pearson's chi-squared test was used to 
compare the frequency of specific symptoms. A p-value of less than 0.05 was 
considered statistically significant. Anova test has been used to explore quantitative 
differences in the protein expression between T0, T1 and T2 whole saliva samples. The 
significance of the differences was expressed by p-value <0.05. 
The concentration of specific proteins in the samples by ELISA kits was determined by 
comparing the O.D. of the samples to the standard curve. The significance of the 
differences (p-value < 0.05) was calculated by Student t test for paired data. 
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RESULTS 
 
Clinical assessment 
 
The demographic characteristics and the treatment regimes of the patients enrolling in 
the study are shown in Table 4. 
 
 
Table 4. Demographic and baseline characteristics of 41 FM patients.  
 Balneotherapy group 
(N=20) 
Mud bath group 
(N=21) 
Sex 1M, 19F 1M, 20F* 
Age (years) (mean±SD) 54.00±7.22 (42-68) 52.81±10.26 (31-69) 
Height (cm) (mean±SD) 161.66±5.78 (150-176 cm) 162.30±5.37 (155-174 cm) 
Weight (kg) ) (mean±SD) 69.84± 15.53 (51-107 kg) 69.55±12.60 (55-100 kg) 
Duration of symptoms (years) 
(mean±SD) 
11.40±8.24 11.65±7.85 
Married 16 13 
Divorced 0 3 
Widow 2 1 
Unmarried 2 4 
Occupational status 12 working, 5 housewife, 3 
retired 
13 working, 6 housewife, 
2 retired 
Hormonal status 25 post menopausal 11 post menopausal 
Smoker 7 3 
*1 of these patients left the study after T1 because of a diagnosis of breast cancer. 
 
 
 
 
Analyzing data all together (balneotherapy plus mud-bath therapy treatment) we showed 
significant improvement of FIQ (p<0.05) and VAS pain (p<0.01) after two weeks of 
treatment and the data are reported in Table 5. 
 
46 
 
 
TPi = Tender Points count 
 
 
 
 
 
 
 
 
Table 5. Results of outcome measures of patients analyzed all together 
(balneotherapy+mud-bath therapy) (median, min-max). 
 T0(baseline) T1 (2 weeks) T2 (12 weeks) Friedman p 
VAS 
Pain  8 (3-10)* 6 (0-10)* 7 (1-10) 13.020 P<0.01 
Fatigue  8 (0-10) 7 (0-10) 8 (0-10) 3.417 NS 
Anxiety  6 (1-9) 5 (0-10) 5.2 (1-10) 5.285 NS 
Depression  5 (0-9) 4 (0-9) 3 (1-10) 3.872 NS 
FIQ    63.2 (18.1-98.0)* 54.10 (4.4-93.2)* 58.4 (6.6-93.7)   5.902 P<0.05 
TPi 18 (4-18) 18 (2.9-18) 18 (2-18) 0.568 NS 
SF-36 subitems 
PF-physical functioning 55 (5-85) 55 (15-95) 55 (15-90) 4.950 NS 
RP physical role 0 (0-100) 0 (0-100) 0 (0-100) 9.812 NS 
BP bodily pain 30 (0-72) 32 (0-61) 32 (0-100) 3.333 NS 
GH general health 35 (10-86) 37 (0-92) 35 (0-82) 3.315 NS 
VT vitality 40 (0-85) 35 (0-90) 35 (0-90) 0.727 NS 
SF social functioning   50 (0-100) 50 (0-100) 50 (0-100) 1.141 NS 
ER emotional role 0 (0-100) 33 (0-100) 33 (0-100) 3.282 NS 
MH mental health 60 (4-100) 60 (4-100) 56 (0-92) 3.081 NS 
FACIT 25 (4-51) 23 (0-48) 24.5 (0-45) 4.637 NS 
HAQ 0.7 (0-2) 0.7 (0-4) 0.7 (0-2) 0.797 NS 
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The clinical characteristics of patients allocated to mud-bath therapy or balneotherapy 
are shown in Table 6 and Table 7, respectively. No statistically-significant difference of 
demographic or clinical characteristics between the two groups of patients, assigned to 
balneotherapy or to mud-bath therapy, was observed at the beginning of the study. 
The patients who received only mud-bath therapy (Tab. 6) showed a significant 
improvement of the VAS pain (T0: 8 (3-10)vs T2: 6 (1-9) p<0.05), FIQ values (T0: 70 
(18.1-81.8) vs  T2: 58.4 (12.4-87.4), p<0.05) and of the domain ―physical role‖ of the 
SF-36 questionnaire (0 (0-75) vs 0 (0-100) vs 25 (0-100), p<0.05) after 12 week thermal 
program. VAS fatigue slightly decreased from T0 to T1 and to T2. The SF-36 domains 
―bodily pain‖, ―emotional role‖, ―social functioning‖ and ―physical role‖ tended to 
increase from T0 to T1 to T2, suggesting an improvement following the mud-bath 
treatment. FACIT and HAQ did not change during the three times T0, T1, T2 . 
In this group of patients it has been observed a significant reduced percentage of the 
frequency of tingling (T0: 76%, T1: 43%, T2: 33%, T0 vs T1, P<0.05; T0 vs T2 
,P<0.01). 
The personal comments of patients treated with mud-bath were: 58% of patients 
reported improvement in symptoms at both T1 and T2, 16% patients only at T1, 5% 
patients only at T2, 21% of patients did not reported effects. In particular, this group of 
patients reported improvement in pain, asthenia, muscle stiffness and sleep, feeling 
more smoothly even if the present pain, pain relief in some parts of the body with 
persistence in others. 
48 
 
TPi = Tender Points count 
 
 
The group of patients allocated to balneotherapy (Tab. 7) showed a significant 
improvement of VAS pain which decrease from T0 to T1 (8 (3-10) vs 7 (1-9) (p<0.05). 
They showed a slight improvement of the following clinical parameters: VAS fatigue, 
FIQ values, VAS anxiety and VAS depression which slightly decrease from T0 to T1 
and then return to values close to the initial value at T2. Tender points count did not 
change from T0-T1-T2. The SF36 domains tend to increase from T0 to T1 and then 
return to values close to the initial value at T2 (except for the domain emotional role 
Table 6. Results of outcome measures of patients assigned to mud-bath therapy 
(median, min-max). 
 T0(baseline) T1 (2 weeks) T2 (12 weeks) Friedman p 
VAS 
Pain  8 (3-10)* 7 (1-9) 6 (1-9)*  8.708 P<0.05 
Fatigue  9 (2-10) 8 (1-10) 8 (3-10)  2.696 NS 
Anxiety  6 (1-9) 5 (0-10) 5.2 (1-10)  0.394 NS 
Depression  5 (0-9) 4 (0-9) 3 (1-10)  0.184 NS 
FIQ 70 (18.1-81.8)* 59.4 (9.6-78.3) 58.4 (12.4-87.4)* 7.238 P<0.05 
TP 18 (4-18) 16 (4-18) 16 (2-18)  5.920 NS 
SF-36 subitems 
PF-physical functioning 55 (5-85) 50 (15-80) 55 (15-90)  5.787 NS 
RP physical role 0 (0-75)* 0 (0-100) 25 (0-100)*  11.31 p<0.05 
BP bodily pain 22 (10-51) 30 (10-61) 32 (22-84)  4.964 NS 
GH general health 35 (20-86) 40 (0-92) 35 (20-82)  0.591 NS 
VT vitality 40 (15-85) 35 (5-85) 35 (1-80)  1.333 NS 
SF social functioning 50 (25-100) 50 (0-100) 50 (12-100)  0.268 NS 
ER emotional role 33 (0-100) 33 (0-100) 33 (0-100)  2.000 NS 
MH mental health 64 (24-100) 60 (24-100) 60 (16-84)  1.684 NS 
FACIT 25 (10-37) 22 (2-48) 23 (6-38)  1.675 NS 
HAQ 0.7 (0.1-2.0) 0.8 (0.1-4.0) 0.6 (0.1-1.7)  2.658 NS 
49 
 
that tend to increase also at T2). Also FACIT tend to decrease from T0 to T1. HAQ 
values remained unchanged in the three times of observations. 
In this group of patients the frequency of characteristic symptoms remain unchanged 
after thermal treatment. The personal comments of patients are: 21% of patients 
reported improvement in symptoms at both T1 and T2, 21% patients only at T1, 21% 
patients only at T2, 37% of patients did not reported any effects. In particular, patients 
reported improvement in pain and sleep, feeling more smoothly despite the presence of 
pain (when persisted) and a reduction of cramping and headaches. The percentage of 
specific symptoms of the disease did not change at the three times in the group of 
patients treated with balneotherapy. 
Psychiatric evaluations revealed 7 patients assigned to mud-bath therapy were suffering 
from psychiatric comorbidity (35%) of which 1 with current disease (panic) and 6 with 
lifetime disease (3 panic, 3 depression). In the group of patients assigned to 
balneotherapy 9 patients were suffering from psychiatric comorbidity (45%) of which 2 
with current disease (1 panic and 1 depression) and 7 with lifetime disease (4 panic, 2 
depression, 1 obsessive compulsive disorder). 
Balneotherapy and mud-bath therapy were well tolerated in all patients. Only one 
patients, belonging to mud-bath group, left the study after the weeks treatment because 
the onset of breast cancer. 
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Table 7. Results of outcome measures of patients assigned to balneotherapy (median, min-
max). 
 T0(baseline) T1 (2 weeks) T2 (12 weeks) Friedman p 
VAS 
Pain  7.5 (3-10)* 5.0 (0-10)* 7.5 (1-10) 8.394 P<0.05 
Fatigue  8 (0-10) 7.0 (0-10) 8 (0-10) 1.069 NS 
Anxiety  8 (1-10) 5 (0-10) 7 (0-10) 7.298 NS 
Depression  6.5 (0-10) 5 (0-10) 6 (0-10) 5.938 NS 
FIQ 61.8 (31.7-98.0) 47.3 (4.4-93.2) 61.2 (6.6-93.7) 3.900 NS 
TPi 17.5 (8-18) 18 (10-18) 18 (8-18) 2.178 NS 
SF-36 subitems 
PF-physical functioning 62.5 (25-85) 60 (25-95) 58 (15-90) 1.909 NS 
RP physical role 0 (0-100) 0 (0-100) 0 (0-37.5) 0.889 NS 
BP bodily pain 32 (0-72 ) 41 (0-61) 30.5 (0-100) 5.265 NS 
GH general health 33.5 (10-76) 37 (15-72) 30.5 (0-67) 5.083 NS 
VT vitality 37.5 (0-80) 35 (0-90) 35.5 (0-90) 0.113 NS 
SF social functioning 50 (0-100) 56 (0-75) 50 (0-100) 1.279 NS 
ER emotional role 0 (0-100) 33 (0-100) 36.5 (0-100) 0.571 NS 
MH mental health 52 (4-92) 58 (4-96) 52 (0-92) 4.111 NS 
FACIT 24.5 (4-51) 23 (0-43) 25 (0-45) 3.143 NS 
HAQ 0.5 (0-1.5) 0.6 (0-1.5) 0.7 (0-2.1) 5.000 NS 
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Determination of biochemical parameters: evaluation of oxytocin, BDNF, 
ATP and serotonin transporter levels during therapy 
 
Tables 8a and 8b resume results of biochemical parameters in relation with treatment 
and response on time. Biochemical evaluations of patients assigned to mud-bath therapy 
are reported in table 8a, those relating to the balneotherapy are in the table 8b. 
Nonetheless the high variability of biochemical parameters as showed from high values 
of SD, however a significant decrease of neuropeptide concentrations were observed 
both after balneotherapy and mud-bath therapy when assayed after twelve weeks. As far 
as SERT is concerned a small decrease of affinity of about two fold of specific 
radioligand was observed at T2 with respect T0 time.  
 
 
Table 8a. Results of biochemical evaluations of patients assigned to mud-bath therapy  
(mean ± sd). 
 MUD-BATH THERAPY 
 T0 T1 T2 
Oxytocin (pg/ml) 17.56± 5.9 17.7 ± 6.9 14.99±4.8 
BDNF s (pg/ml) 9838±2261 9087±2634 8524±2492** 
SERT Bmax(fmol/mg) 1122± 443 1201 ± 371 1165 ± 473 
SERT, Kd(nM) 0.048±0.044 0.05 ± 0.05 0.08± 0.06 
ATP (fmol/plt) 0.025±0.008 0.021±0.006 0.024± 0.006 
Significant differences observed between T2 vs T0 are based on Wilcoxon  non parametric 
matched pairs test (*p<0.05; ** p<0.01)  
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Table 8b. Results of biochemical evaluations of patients assigned to balneotherapy  
(mean ± sd). 
 BALNEOTHERAPY 
 T0 T1 T2 
Oxytocin (pg/ml) 14.2 ± 7.25 15.28 ± 8.4 16.5±8.19 
BDNF s (pg/ml) 10450±1493 10260±1739 9362±1849* 
SERT Bmax(fmol/mg) 912  ± 334 1011±466 913± 471 
SERT, Kd(nM) 0.035±0.008 0.06±0.07 0.08± 0.07 
ATP (fmol/plt) 0.021 ± 0.008 0.026±0.009 0.02±0.006 
Significant differences observed between T2 vs T0 are based on Wilcoxon  non parametric 
matched pairs test (*p<0.05; ** p<0.01)  
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Identification of proteins (responsive) to balneotherapy and mud-bath 
therapy treatment. 
 
A comparative proteomic analysis was performed on WS samples using 2-DE followed 
by nanoLC-ESI-MS/MS analysis. The computational analysis of 2DE gel images of 
pools from balneotherapy and mud-bath theraphy before and after treatment showed a 
significant difference of expression of four spots. Figure 1A shows a representative 2DE 
WS image where the spots of interest are circled. Moreover, in Figure 1B are 
represented the enlarged images of these spots for balneotherapy and mud-bath therapy 
pools at three time (T0, T1, T2).  
 
 
        1A) 
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      1B) 
 
 
Figure 1. A) Representative 2-DE gel map of salivary proteins in FM patient. A total of 200 μg 
proteins were separated by 2-DE using 18 cm pH 3–10L strip and 12.5% SDS-PAGE. Proteins 
were detected by Ruthenium staining. The map was analyzed by the ProgenesisSameSpot 
(Nonlinear Dynamics) software. B) The enlarged images represented the protein spot 
differentially expressed in Balneotherapy and Mud-bath therapy for three time of treatment 
(T0,T1 and T2). Spot numbers indicate all the proteins differentially expressed  identified by 
nanoLC-ESI-MS/MS and refer to the number reported in Table 8. 
 
 
 
The differentially expressed protein spots were subjected to nano LC-ESI-MS/MS 
analysis and identified. A list of identified proteins, Molecular Weight, Isoelectric point, 
score and coverage values of MS/MS, are shown in Table 9a. Among proteins 
responsive to treatment, PGAM1, TALDO1 and RabGDP were previously described by 
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us as potential biomarkers of FM [17], [20] and zinc alpha 2 glycoprotein resulted the 
most responsive to treatment. Instead, in Table 9b are reported the fold variation of each 
protein spot 
 
 
 
ID No =Accession Number; MW = Molecular Weight; pI = Isoelectric point;  ob = observed;                 
th= theorical;  Mat. Pep. = Matched peptides; Cov. = Coverage; B.I.S. =Best Ion Score 
 
 
 
 
 
 
Table 9a.  MS/MS data of protein spots differentially expressed in whole saliva of FM 
patients following thermal treatments. 
# 
Spot ID. No Protein Name 
Gene 
name 
MW pI Mat. 
pep. 
Cov. 
(%) 
B.
I.
S. ob. th. ob. th. 
469 P50395 
Rab GDP dissociation 
inhibitor beta 
GDI2 56 51 6.0 6.1 8 19 70 
576 P25311 Zinc-alpha-2-
glycoprotein 
AZGP1 48 34 5.6 5.7 2 12 65 
706 P37837 Transaldolase TALDO1 
 
41 37 6 6.3 7 22 76 
2268 P18669 Phosphoglycerate  
Mutase 1 
PGAM1 34 29 6.7 6.6 2 5 46 
Table 9b. Fold Variation expressed as ratio  
# Spot 
Balneotherapy Mud-bath therapy 
T1/T0 T2/T1 T2/T0 T1/T0 T2/T1 T2/T0 
469 1.4 1.2 1.1 1.4 1.4 1.3 
576 1.2 1.4 1.2 1.2 2.4 1.8 
706 1.2 1.2 1.4 1.2 1.5 1.4 
2268 1.3 1.3 1 1.2 1.1 1.4 
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Validation of Transaldolase (TALDO1), Phosphoglicerate Mutase1 
(PGAM1) and Alpha-2-Glycoprotein1, Zinc Binding (aZGP1) by ELISA Kit 
analysis 
 
ELISA Kit analysis was used to validate the difference in expression of proteins of 
interest of Transaldolase (TALDO1), Phosphoglicerate Mutase1 (PGAM1) and Alpha 
2-Glycoprotein1, Zinc Binding (aZGP1) in WS samples of individual patients 
distinguished for type and time of treatment; the concentration of the specific protein 
was determined using a standard calibration curve. The results are showed in Table 10.  
 
Tab  
Table 10. ELISA assays of Phosphoglicerate Mutase 1, Transaldolasi and Zinc-alpha 
2 glycoprotein in WS of FM patients. 
Phosphoglicerate 
Mutase 1 
BALNEOTHERAPY 
 
MUD-BATH THERAPY 
Time of treatment T0 T1 T2  T0 T1 T2 
Mean (OD) 27,74 19,42 24,52  35,98 33,68 17,72 
SEM 6,27 4,59 6,25  6,92 7,88 4,35 
Time Ratio T0/T1 T1/T2 T0/T2 
 
T0/T1 T1/T2 T0/T2 
Paired t test (p values) 0,10 0,39 1,00  0,13 0,24 0,05* 
    
Transaldolase 
 
BALNEOTHERAPY 
 
MUD-BATH THERAPY 
Time of treatment T0 T1 T2  T0 T1 T2 
Mean (OD) 0,06 0,17 0,09  0,22 0,25 0,36 
SEM 0,03 0,07 0,03  0,08 0,05 0,15 
Time Ratio T0/T1 T1/T2 T0/T2 
 
T0/T1 T1/T2 T0/T2 
Paired t test (p values) 0,08 0,09 0,70  0,73 0,46 0,26 
    
Zinc-alpha-2  
glycoprotein 
BALNEOTHERAPY 
 
MUD-BATH THERAPY 
Time of treatment T0 T1 T2  T0 T1 T2 
Mean (OD) 20,85 22,84 18,84  22,19 17,52 14,49 
SEM 9,05 8,79 7,88  5,72 4,65 5,04 
Time Ratio T0/T1 T1/T2 T0/T2 
 
T0/T1 T1/T2 T0/T2 
Paired t test (p values) 0,47 0,07 0,13  0,69 0,03* 0,01** 
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The figure 2 shows the histogram of the means±SEM of the concentrations of the 
proteins of interest in WS of FM patients between the three time of collection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Each bar represents the mean±SEM of the mean of each protein concentrations in WS of FM 
patients at each time (T0,T1,T2). Significant differences are based on t test; (*p<0.05, **p<0.01, 
***p<0.001). 
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DISCUSSION   
FM is a chronic non-inflammatory musculoskeletal disorder, characterized by a 
generalized pain condition often accompanied by a wide range of other unspecific 
symptoms, such as fatigue, sleep disturbance, headache, mood disorders, anxiety, 
depression, cognitive dysfunction, sexual dysfunction and autonomic complaints like 
irritable bowel syndrome. FM is more common amongst women than men and affects 
between 2% and 4% of the general population. In 1990 the American College of 
Rheumatology (ACR) established criteria for classification of FM [1], and more 
recently Wolfe and colleagues [41] have proposed new diagnostic criteria. The 
establishment of these guidelines for diagnosis has permitted the performance of 
research studies by investigators in many countries contributing to the understanding of 
the mechanisms that underlie in FM [14]. A plethora of objective markers has been 
shown to be abnormal in FM, and some of these may even have characteristics of a 
biomarker because they are not only abnormal in patients versus controls, but also 
change in response to changes in symptoms, but at present no specific markers have 
been found [13]. The problem lies in the presence of too many data, often controversial, 
rather than in a lack of data [17]. The mechanisms underlying the FM are still unclear 
and largely unknown, and as a direct consequence, the diagnosis is very difficult. The 
difficulty is that laboratory tests are normal and many of the symptoms mimic those of 
other conditions including many rheumatic complaints, psychiatric conditions and other 
somatic disorders. It is therefore important to exclude rheumatic disorders before 
proceeding to a diagnosis of FM. Then, to make a diagnosis of FM, the patient, in 
addition to reporting a widespread pain for at least 3 months and a painful response due 
to digital pressure of 11 of the 18 tender points, must be subjected to the Fibromyalgia 
Impact Questionnaire (FIQ) (Table 1) that gives a good idea of the full range of 
symptoms that are regularly found in FM. Therefore, the diagnosis of FM is basically 
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clinical [13] and the lack of easily accessible laboratory measures makes difficult to 
collect under the term of FM, patients presenting with homogeneous features and 
prognosis [39], [40]. At present, although proteomic studies have shown alterations in 
the expression of certain proteins in the saliva of FM patients compared to controls [20], 
there are no specific markers of FM. Several studies have identified alterations in the 
serum or plasma concentration of some neuromodulators/neurotransmitters, such as 
Oxytocin [22], BDNF [26]-[30], SERT [19] and ATP [34], [35] in patients with FM 
than in healthy subjects. The complexity of the disease means that there isn‘t a 
therapeutic treatment standards. The treatment of FM symptoms requires a multimodal 
approach that has to consider somatic aspects (i.e., pain onset, location, quality, 
quantity, duration), emotional aspects (i.e., mood and anxiety), cognitive aspects (i.e., 
coping styles, beliefs about pain), and environmental aspects (i.e., social context and 
patient relationships). From the pharmacological point of view, categories of drugs most 
commonly used are: analgesics, antidepressants, muscle relaxants and anti-epileptics. 
The current recommendations suggest that the optimal treatment of FM requires a 
multidisciplinary approach with a combination of non-pharmacological and 
pharmacological treatment modalities tailored according to pain intensity, function, 
associated features, such as depression, fatigue and sleep disturbances, decided through 
discussion with the patient, so the main strategy is symptom management [59]-[62]. Among 
non-pharmacological interventions the most used are physical therapy, psychotherapy, 
acupuncture, massage, and balneotherapy [63]-[66]. In the context of complementary 
medicine, the spa therapy, which includes hydrotherapy, balneotherapy, physiotherapy, 
mud-pack therapy and exercise [67]-[69],  is known to be one of the most recognized 
therapeutic strategies for the treatment of rheumatic (as well as dermatological)  
disorder to pain alleviation [70]. The efficacy of this treatment for these indications 
underscores the applicability of spa therapy for the treatment of FM [71] but despite the 
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long history and popularity, there are not many randomized controlled trials that 
demonstrate their effect on FM patients [71], and only a few were paralleled by a 
biological evaluation. Therefore, the aim of this work was to understand the impact that 
two different types of thermal treatment (balneotherapy and mud-bath therapy) have on 
patients with FM, through the application of a multiple approach: the classical 
evaluation of clinical type of patients (before, after and three months after treatment), it 
has also made an assessment of biochemical and proteomic type. 
Overall, our results indicate that both spa treatment are beneficial in patients affected by 
FM. In general the percentage of patients who self-reported positive effects of spa 
therapy was higher in the group treated with mud-bath than those treated with 
balneotherapy. In particular an improvement of FIQ and a decrease of pain were 
evidenced. The comparison of two different spa treatments showed that both mud-bath 
and balneotherapy were able to relieve the pain although with different effect span. In 
fact, mud-bath therapy showed significant improvement of the pain, the FIQ and the 
domain ―physical role‖ which persist up to 12 weeks. Instead balneotherapy, showed a 
significant reduction of the pain immediately after the two weeks of treatment, but at 12 
weeks pain values returned near to  initial values, similarly slight improvement of 
fatigue and quality of life occurred (Tab. 5, 6, 7). 
Discordant results were reported in literature about the long lasting effects of 
balneotherapy [72], [77], [78], [79], [117]. Buskila et al. [77], evaluate the effectiveness 
of balneotherapy on patients with FM at the Dead Sea. All participants stayed for 10 
days at a Dead Sea spa. The improvement was especially notable in the treatment group 
and it persisted even after 3 months. Neumann and colleagues [78] observed an 
improvement in physical aspects of QoL of FM patients treated with balneotherapy 
which lasted usually 3 months, but on psychological measures the improvements was 
shorter. Moreover, as observed by Evcik et al [79], the extension of balneotherapy time 
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treatment from one to three weeks led to positive effect which persisted even after 6 
months not only for the FIQ, but also for the pain and the tender point count. 
As mud-bath-therapy as concerned our results agree with those published by Fioravanti 
et al. [72] in a multicentric single blind randomized clinical trial study where the effects 
of a cycle of 12 mud-packs and thermal bath treatment over a period of 2 weeks was 
analyzed on 40 FM patients. The researchers recorded a significant improvement of 
FIQ, tender point count, VAS for minor symptoms and HAQ after thermal therapy and 
after 16 weeks.  
In addition, FM patients enrolled in our study have been carefully characterized and 
evaluated by trained psychiatrists using the Structured Clinical Interview Scale (SCID) 
for DSM-IV, detecting the presence of psychiatric comorbidity (lifetime and current) in 
about 40% of FM patients. Published works are lacking of psychiatric evaluations and 
anyway, when present, they are carried out through self-assessment instrument like the 
Beck Depression Inventory Index, which evaluate only depression [22], [81]. 
The mechanisms by which spa therapies relieve symptoms are not fully understood, 
although they probably include thermal, mechanical, chemical and immunomodulatory 
effects. Moreover, thermal therapy brings about a decrease of stress sensation, 
relaxation and a sense of well-being which have been related to an increase of serum 
levels of pituitary hormones and endogenous opiates such as endorphins [70], [118], 
[119], [120]. In spite of this, there are different reports which discuss about the role of 
neuropeptides and neurotransmitters in the pathophysiological mechanisms responsible 
for the symptoms in the FM. Among these, the neuropeptide oxytocin and the 
neurotrophic factor BDNF have been studied in FM patients with a particular attention 
to their correlation with features such as anxiety and depression. Oxytocin is known to 
have anti-nociceptive and analgesic effects as well as anxiolytic and sedative effects, in 
addition an anti-depressive and an anti-stress effects have been documented. 
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Differences of serum oxytocin expression in FM patients has been reported by 
Anderberg et al. [22]  which suggested that depressed FM patients have reduced level of 
neuropeptide with respect to non-depressed FM patients. No significant change of 
oxytocin concentration after balneotherapy and mud-bath therapy was observed in our 
patients. As BDNF is concerned, different roles have been hypothesized in FM and 
other chronic pain conditions suggesting a pivotal role of this neuromodulator in these 
conditions. Recent findings have suggested an involvement of BDNF as a 
neuromediator of hyperalgesia and spinal central sensitization. Increased BDNF serum 
levels were shown in FM patients with respect healthy subjects, but  there are different 
and controversial reports which discuss about the role of BDNF in the 
pathophysiological mechanisms responsible for the symptoms in the FM, particularly 
anxiety and depression [29], [30], [26], [28]. Our results indicate that spa therapy 
reduced the BDNF serum concentration by about 10–15% only after 12 weeks from the 
treatment. We believe that further studies are needed to clarify if these neuropeptides 
could be indicators of the beneficial thermal effects. Additionally, among the 
neurotransmitters, it has recently been suggested that altered serotonergic neuronal 
function might be related to the pathophysiology of FM [121], [122]. In a previous 
study [19], it was reported a decrease in the density and rate of platelet SERT in patients 
with FM respect to healthy subjects and it was also proposed a specific role for SERT in 
the pathogenesis of FM. A reduced density and rate of SERT are consistent with 
previous observations indicating that levels of 5-HT are altered in patients with FM 
[19].  In this study comparable mean values of Kd and Bmax were found in FM 
patients, but no significant changes both in terms of affinity and of the total number of 
SERT were observed after thermal treatment. Finally, from the biochemical point of 
view, in this study no significant change of ATP concentrations was observed after both 
thermal treatments.  All biochemical data are summarized in Table 8a and 8b. 
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Previously, our group performed a comparative proteomic analysis of FM WS, by 
combining 2DE and MALDI-TOF-MS [20]. The most relevant observation which 
emerged from the data analysis was the exclusive and significant over-expression of 
TALDO1 and PGAM1 in FM samples with respect to healthy subjects suggesting that 
this could be involved in limiting oxidative damage to tissues [20], [17]. Based upon all 
these observations, in this study we evaluated if the change of protein expressions can 
occur in response to thermal treatments. Using a combination of 2DE (Fig. 1A, 1B) and 
nano-LC-ESI/MS/MS spectrometry techniques (Tab. 9a, 9b)  we compared FM WS 
protein profiles of a randomized pool of patients at different times from each treatment. 
Only four proteins showed appreciable change (ratio range from 1.1 to 2.4) of their 
expression values in response to treatment. The quantitative evaluation and the 
significance of these protein expression variations were determined by using the 
specific ELISA kit (Tab. 10; Fig.2). We observed a high variability of protein con-
centrations in both treatment groups and also in different times. Significant differences 
were observed only for PGAM1 and Zinc-alpha 2 glycoprotein (AZGP1). In fact, a 
reduction of the expression values toward normal values was found in WS of the 
patients treated with mud-bath therapy, particularly at 12
th 
week suggesting an 
improvement of FM patients. A role of the adipokine AZGP1 in the activation of AMP 
kinase, an important regulator of energy metabolism, in human skeletal muscle cells has 
emerged [123]. The mechanism may be involved in mediating the effects of AZGP1 in 
relation to increased energy utilization. All in all we can see the protein up regulation as 
a response to an increase of the oxidative stress, responsive to mud bath treatment.  
In conclusion, our results show that the thermal treatment might have a beneficial effect 
on the specific symptoms of the disease, in particular while balneotherapy gives results 
that in most patients occur after the end of the treatment, but which are no longer 
noticeable after 3 months, the mud-bath treatment gives more lasting results. Indeed, a 
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combined treatment of balneotherapy plus mud-bath treatment is advisable for patients 
suffering from FM. On the other hand, respect to the biological effects, the mud-bath 
therapy appears to be the best treatment producing a statistical significant reduction of 
level both of neuropeptide, such as BDNF, and proteins, such as PGAM1 and AZGP1 
which usually resulted up regulated in FM patients [17], [26], [28]. In our study other 
factors which could contribute to the clinical improvement after a spa treatment, such as 
the pleasant scenery and the absence of work duties [77], [117] were not considered. In 
fact, the patients (except two) did not stay in the spa, but they were resident in areas 
surrounding it, continued their work activities and the time that the patients spent in the 
spa center was limited to the treatment. In this way the observed improvement of 
symptoms was only dependent on the spa therapy itself. 
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